Monthly Archives: October 2011

BIO Investor Forum: Supporting Our Clients’ Participation as Panelists, Presenters

Last  week took us to San Francisco for the 10th Annual BIO Investor Forum, an investor conference focused on private and emerging public biotech companies. Multiple clients were involved in the conference either as presenters or panel participants discussing key issues affecting the biotechnology industry. Russo Partners was there to support their activities.

Clients participating on panels included Sutro Biopharma and GlobeImmune. William Newell, chief executive officer of Sutro Biopharma, a company with a biochemical protein synthesis technology platform enabling the design and development of novel proteins that previously have been inaccessible or difficult to produce, provided insight into the future of biosimilars and development strategies on the panel titled Biologics: Billions from BioBetters?

On another panel titled Immunotherapy: Heal Thyself, Timothy Rodell, M.D., president and chief executive officer of GlobeImmune, a company developing therapeutic vaccines for cancer and infectious diseases, discussed the promising future of immunotherapies.

Our clients Anaphore and Flexion Therapeutics also participated in the conference as presenting companies. Brinson Patrick Securities also took advantage of this conference for onsite networking and media opportunities.

At a rich networking event such as BIO Investor Forum, Russo Partners works to maximize our clients’ time spent at the conference by connecting the company executives to key members of the life sciences community.

We look forward to preparing our clients to deliver their “stories” at the next industry event.

Congratulations to Cellular Dynamics International (CDI), Gold Winner of The Wall Street Journal’s 2011 Technology Innovation Awards

Receiving an award is a great way for a company to raise its profile and
gain recognition for its technology or therapeutic. Throughout the year multiple award programs are applicable to our clients, including The Scientist’s Top 10 Innovations, the MIT International Technology Awards and the honor our client CDI received this week, The Wall Street Journal’s 2011 Technology Innovation Gold Award.

Before Russo Partners begins the process of submitting a client for consideration for an award, several criteria must first be met. It is important to understand the award and what is needed in order to be considered. What is the publication looking for? What does a company need to have in order to qualify? This can also be determined by looking at past winners and verifying that the company is similar to others in the category; for instance, you might consider whether a company also has an innovative technology in the vein of a past winner or is comparable in size to one that came before.

Secondly, the award must support the client’s communications objectives. Will this award benefit perception? Is the award credible? An award from The Wall Street Journal or The Scientist is highly regarded by others in the investment and scientific communities and is undoubtedly beneficial for our clients. Receiving an award from a prestigious publication raises awareness and adds validation to the technology or therapeutic being recognized.

As CDI’s recent recognition demonstrates, when all of these pieces are in place, the payoff is certainly worth it.

Below are links to The Wall Street Journal article about the winners, the article profiling CDI and a video describing the winners.

The Wall Street Journal Article About the Winners

The Wall Street Journal Article Profiling CDI

Wall Street Journal Video Describing the Winners

Developing the Company “Story”

Before a company begins a public relations program, it is key that the executives and PR advisors develop the company “story” — the key messaging points the company would like to convey to its target audiences. For life science companies, target audiences may range from investors and potential partners to physicians and patients. However, before delivering a story it is important to first gain key insights from the target audiences.

This is where story development comes into play.

The most efficient way to determine what target audiences understand and value about a company, and what’s not quite clear, is to ask them. At Russo Partners, we have expertise in creating thoughtful and insightful questions designed to elicit perspective from the individuals in each target audience, as well as the executive management team. The questions are specifically tailored to each company and audience with the company’s final objectives in mind.

We quantify and analyze these findings to develop the proposed messages and recommendations for the company’s communications moving forward. These messages are not what we think we should say; instead they are designed to communicate in a manner that properly shape audience mindsets and lead to action — for example, an inquiry from a prospective investor.

The findings are then presented to the client and serve as the basis for discussion and interactive exercises. Key messaging points are finalized and following the workshop we capture the messages in a story checklist, which can be applied to all of the company’s communication tools.

Once a company has developed and identified its “story,” the leadership team can implement their communications program, confident that their key messages will resonate with each audience.

Below is a sample slide displaying results obtained from an investor audience.

Slide displaying sample results

 

Obesity: The Week in Review

If you totaled the number of extra pounds each person in our country weighs, as a whole our nation is 5 billion pounds overweight. It is clear that diet and exercise are not enough to combat the growing epidemic of obesity. Innovative therapeutics and technologies must be developed and pursed in order to treat the numbers of people affected by this condition.

In recognition of this need, obesity was a hot topic this week, as multiple events discussing the use of therapeutics to control this indication were held around the nation.

In New York, a world-renowned authority on hormones, Ronald M. Evans, Ph.D., spoke at a NY Salkexcellerators event about the availability of drugs that could simulate the effect of exercise and reduce muscle wasting. When he is not busy conducting research at the Salk institute about hormones and their functions in normal activities and disease, Dr. Evans enjoys spending time with his daughter, Russo Partners team member Lena Evans.

Further down the coast in Orlando, our client Arena Pharmaceuticals presented at The Obesity Society’s Annual Scientific Meeting. One of the world’s largest gatherings of obesity professionals, leading obesity scientists and clinicians were in attendance to discuss new research findings to help promote treatments for patients with this disease.

With the levels of obesity in our nation growing, we are glad to see that research and therapeutics are under development to help combat the increasing incidence of this disease.